GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Piotroski F-Score

ContraFect (ContraFect) Piotroski F-Score : 0 (As of May. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ContraFect Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 0 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ContraFect has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for ContraFect's Piotroski F-Score or its related term are showing as below:

During the past 11 years, the highest Piotroski F-Score of ContraFect was 4. The lowest was 0. And the median was 2.


ContraFect Piotroski F-Score Historical Data

The historical data trend for ContraFect's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect Piotroski F-Score Chart

ContraFect Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 1.00 2.00 2.00 1.00

ContraFect Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.00 1.00 - -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was -9.84 + -1.371 + -7.568 + -5.359 = $-24.14 Mil.
Cash Flow from Operations was -9.968 + -8.798 + -8.151 + -8.669 = $-35.59 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was
(23.034 + 20.679 + 20.552 + 19.252 + 9.125) / 5 = $18.5284 Mil.
Total Assets at the begining of this year (Sep22) was $23.03 Mil.
Long-Term Debt & Capital Lease Obligation was $1.87 Mil.
Total Current Assets was $6.52 Mil.
Total Current Liabilities was $12.32 Mil.
Net Income was -4.399 + -20.157 + -18.089 + -17.067 = $-59.71 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was
(77.842 + 66.762 + 56.04 + 40.798 + 23.034) / 5 = $52.8952 Mil.
Total Assets at the begining of last year (Sep21) was $77.84 Mil.
Long-Term Debt & Capital Lease Obligation was $2.31 Mil.
Total Current Assets was $20.05 Mil.
Total Current Liabilities was $23.78 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ContraFect's current Net Income (TTM) was -24.14. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ContraFect's current Cash Flow from Operations (TTM) was -35.59. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=-24.138/23.034
=-1.04792915

ROA (Last Year)=Net Income/Total Assets (Sep21)
=-59.712/77.842
=-0.76709232

ContraFect's return on assets of this year was -1.04792915. ContraFect's return on assets of last year was -0.76709232. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ContraFect's current Net Income (TTM) was -24.14. ContraFect's current Cash Flow from Operations (TTM) was -35.59. ==> -35.59 <= -24.14 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=1.873/18.5284
=0.10108806

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=2.313/52.8952
=0.04372798

ContraFect's gearing of this year was 0.10108806. ContraFect's gearing of last year was 0.04372798. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=6.52/12.323
=0.52909194

Current Ratio (Last Year: Sep22)=Total Current Assets/Total Current Liabilities
=20.049/23.783
=0.8429971

ContraFect's current ratio of this year was 0.52909194. ContraFect's current ratio of last year was 0.8429971. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ContraFect's number of shares in issue this year was 10.705. ContraFect's number of shares in issue last year was 0.492. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

ContraFect's gross margin of this year was . ContraFect's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=0/23.034
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=0/77.842
=0

ContraFect's asset turnover of this year was 0. ContraFect's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+0+0+0+0
=0

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ContraFect has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

ContraFect  (OTCPK:CFRXQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ContraFect Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of ContraFect's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ContraFect (ContraFect) Business Description

Traded in Other Exchanges
N/A
Address
28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Executives
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger officer: VP Finance 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff director 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low director EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi director C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner officer: SVP Business Development 30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 10 percent owner BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd 10 percent owner FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino officer: Chief Medical Officer 757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos officer: General Counsel 207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto director 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421

ContraFect (ContraFect) Headlines

From GuruFocus